Cite
Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions.
MLA
Peters, Stefan. “Comparison of Efficacy of Low- (80 Mg/Day) and High- (160-320 Mg/Day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions.” American Journal of Cardiovascular Drugs, vol. 8, no. 2, Mar. 2008, pp. 83–87. EBSCOhost, https://doi.org/10.1007/BF03256585.
APA
Peters, S. (2008). Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions. American Journal of Cardiovascular Drugs, 8(2), 83–87. https://doi.org/10.1007/BF03256585
Chicago
Peters, Stefan. 2008. “Comparison of Efficacy of Low- (80 Mg/Day) and High- (160-320 Mg/Day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions.” American Journal of Cardiovascular Drugs 8 (2): 83–87. doi:10.1007/BF03256585.